Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia Pharma's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was 円-8.57.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.14.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -33.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for RaQualia Pharma's EPS without NRI or its related term are showing as below:
TSE:4579'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -94.6 Med: 21.6 Max: 92.2
Current: -33.6
During the past 13 years, RaQualia Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 92.20% per year. The lowest was -94.60% per year. And the median was 21.60% per year.
TSE:4579's 3-Year EPS without NRI Growth Rate is ranked worse than 92.04% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs TSE:4579: -33.60
RaQualia Pharma's EPS (Diluted) for the
three
months ended in Mar. 2026 was 円-8.84.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.09.
RaQualia Pharma's EPS (Basic) for the
three
months ended in Mar. 2026 was 円-8.84.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-24.09.
RaQualia Pharma (TSE:4579) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
RaQualia Pharma EPS without NRI Related Terms
RaQualia Pharma EPS without NRI Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, RaQualia Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-24.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a EPS without NRI of 円-24.14 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #1075 out of 1168 companies in the Biotechnology industry, placing it in the top 92%.
Is RaQualia Pharma's EPS without NRI too high?
RaQualia Pharma's current EPS without NRI is 円-24.14. Based on the distribution chart, RaQualia Pharma ranks #1075 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #1075 out of 1168 companies for EPS without NRI. This places RaQualia Pharma in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current EPS without NRI is 円-24.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.31, compared to a current price of 円458.00 — trading 47.6% above its estimated fair value. The current EPS without NRI is 円-24.14. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current EPS without NRI is 円-24.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円458.00 is trading 47.6% above its estimated GF Value™ of 円310.31.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
EPS without NRI: 円-24.14
GF Value™: 円310.31 vs. price of 円458.00 (47.6% above fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score
Get the complete analysis for TSE:4579
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
